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The  saponins  of  Chiococca  alba  are  triterpene  bidesmosides  that  contain  glycidic  moieties  attached
to  the  C-3  and  C-28  carbon  of  their  aglycone.  We  describe  that their  adjuvant  potential  increases  in
direct  relationship  to  the  length  and  hydrophilicity  of  the  C-28  attached  sugar  chain  which  contains:
arabinose–rhamnose  in the  CA2,  arabinose–rhamnose–xylose  in  the  CA3X;  arabinose–rhamnose–apiose
in  the  CA3  and  arabinose–rhamnose–apiose–apiose  in the  CA4  saponin.  The  hydrophile/lipophile  balance
calculated  for  CA2  was  12.7,  for CA3 and  CA3X  was  15.8  and  for  CA4  19.9.  All  saponins  were  formulated
with  the  FML  antigen  for mice  prophylaxis  against  visceral  leishmaniasis.  The  immune  response  was
studied  using  an  ELISA-antibody  assay  and  monitoring  of  the  intradermal  response  (IDR)  to  Leishma-
nia  antigens,  the  cytokine  expression  in  supernatants  and  the  intracellular  staining  of in vitro  cultured
splenocytes.  After  challenge,  signiﬁcant  increases  of IgG  and  IgG2a  antibodies  were  noted  only  in the CA4
vaccinated  mice  that  showed  extended  IDR, higher  IFN-  production  by  CD8+  and  TNF-  production  by
CD4+  T cells,  higher  TNF-  secretion  and  the  highest  reduction  of  the  parasite  load  (78%).  The  increases  in
IDR,  CD4–TNF-,  CD8–IFN-  and  CD8–TNF-  by the  CA4  vaccine  were  strong  correlates  of protection  and
were  signiﬁcantly  correlated  to  the  decrease  of  parasite  load  (p = −0.007).  Protection  generated  by  the
CA4  vaccine  was  mainly  mediated  by  a CD4+  T  cell  and  a TNF-  driven  response  with  a  lower  contribu-
tion  of CD8+  T cells,  as  conﬁrmed  by  an  in  vivo  depletion  with  monoclonal  antibodies  and  by vaccination
assays  in  TNF--receptor  knock-out  mice.  Our  results  conﬁrm  that  the  superiority  of the  CA4  saponin  is
related  to the  higher  hydrophilicity  of  its  longer  carbohydrate  chain.  C. alba  saponins  were  non-toxic  and
only  the  xylose-containing  saponin  CA3X  was  hemolytic  (HD50 = 87  g/ml).  The  increase  in sugar  units
of  the  saponins  is  positively  correlated  to  the  increase  of  IDR  and  to the  decrease  of  parasite  load.. Introduction
Leishmune®, the ﬁrst licensed vaccine against visceral leish-
aniasis has a 76–80% of vaccine efﬁcacy. This veterinary vaccine
rotects 98% of vaccinated dogs and blocks the transmission of the
isease in endemic areas [1–3]. In the Americas and the Mediter-
anean, visceral leishmaniasis is an immunosuppressive zoonotic
isease transmitted from dogs to humans through the byte of a sand
y vector [4]. The disease is fatal in humans and dogs if untreated
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vda. Carlos Chagas 373, Caixa Postal 68040, Cidade Universitária, Ilha do Fundão,
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and treatment is highly toxic and not always efﬁcient. The epidemi-
ological control of the disease includes the treatment of human
cases, insect vector control with insecticides and the culling of
seropositive/infected dogs. Human or canine vaccines are expected
to be effective tools for the prophylactic control of epidemics [5].
The recent canine vaccinations with the Leishmune® vaccine in
Brazil reduced the incidence of human cases, human deaths and
dog prevalence of visceral leishmaniasis in endemic areas [6]. In
districts where the vaccinations occurred the canine and human
incidence decreased or achieved a stabilized plateau while in non-
vaccinated districts the incidences rose [6].
Open access under the Elsevier OA license.Leishmune® is the FML-saponin vaccine [1,3,7,8] composed of
the FML  (Fucose Mannose ligand) antigen [9], a complex glyco-
proteic fraction of Leishmania donovani, and a Quillaja saponaria
saponin adjuvant (Riedel de Haën-Sigma) [revised in 3]. The main
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ctive components of the Leishmune® adjuvant are the well known
S21 saponin and the two  deacylated saponins that only differ from
he QS21 due to the absence of the hydrophobic moiety [10].
Saponins  are a structurally diverse class of natural compounds
ccurring in several plant species. According to previous reports
he most common components of the saponin core are the triter-
enoid and steroid aglycones to which carbohydrate chains are
ttached [11]. They exhibit from one to three straight or branched
ugar chains which most often include d-glucose, l-rhamnose, d-
alactose, d-glucuronic acid, l-arabinose, d-xylose or d-fucose. The
ugar chain can contain from one or more monosaccharide residues,
nd is usually attached at the C-3 of the triterpene [11].
The  correlation between structure and function of saponins
as been the focus of intensive research in order to deﬁne the
ssential moieties for the development of the adjuvant activity
10–15]. Saponins with steroid but not with triterpene aglycones
re considered to be the most hemolytic [12,16]. Alternatively, the
emolytic or membranolytic activity has been attributed to the
ligosaccharide moiety of saponins [13,17–22]. And the saponins
ith two glycidic chains attached to the aglycone, called bidesmo-
idic [10,14], have been shown to be more immunogenic than the
onodesmosidic ones [14].
In the QS21 saponin of Q. saponaria Molina, the induction of
 lymphoproliferative CD8+ T cell response is attributed to the
ormonoterpene hydrophobic moiety while the induction of a
H1 response is related to the C-23-aldehyde of the triterpene
ucleus [15,23]. The different spatial conformation of the C-23 alde-
yde group deﬁnes the type of induced immune response [17].
n enhanced humoral immune response was obtained using an
nriched axial aldehyde-containing sapogenin while an enhanced
ellular immune response (increased DTH and IFN- sera levels)
hat determined a 77% reduction of liver parasitic load was obtained
sing an enriched equatorial aldehyde-containing QuilA-sapogenin
17].
The Q. saponaria saponins, which lack the hydrophobic moi-
ty of QS21, are capable of inducing increases in DTH, CD4+ T
ymphocytes in spleen, IFN- in vitro, body weight gain and a
ronounced reduction of parasite burden in the liver, suggesting
hat the immunoprotective potential of the saponin relies more on
ts carbohydrate chains than on its hydrophobic attached moiety
10]. Similar to QS21, the CP05 saponin of Calliandra pulcherrima is
omposed of a triterpene nucleus with two carbohydrate fractions
ttached to C-3 and C-28, respectively, and one hydrophobic moi-
ty acylated to a sugar attached to C-28 [24]. The chemical removal
f the hydrophobic monoterpene moiety of CP05 did not interfere
ith the protection but the removal of one or two of the carbo-
ydrate chains, however, abolished protection and determined an
ncrease of the parasite load indicating that, as postulated for other
aponins [25–27], and in the case of the CP05 saponin also, the
nduction of protection is directly related to the presence of the
arbohydrate moieties [14].
Considering the relevance of the carbohydrate moieties to the
djuvant potential of saponins, and the evidence that the immuno-
rotective potential increases in direct relation to the number of
ugar units on the carbohydrate chains [19,22] this work investi-
ated, two saponins of Chiococca alba (CA3 and CA4) [28] which
iffer only in one sugar unit. These two saponins were compared in
he murine vaccination against visceral leishmaniasis with the FML
ntigen. The QS21-containing saponin adjuvant of the Leishmune®
accine (saponin R) was used as a positive control.
The CA3 and CA4 saponins of C. alba are two typical Glucuronide
leanane-type Triterpene Carboxylic Acid 3,28-O-Bisdesmosides
GOTCAB). Their structures were recently elucidated [28]. Both
hare a triterpene nucleus to which a glucuronic acid is attached
t C-3 and an apiose–rhamnose and arabinose chain is attached
t C-28 (Fig. 1). The CA4 shows the same triterpene and sugar (2012) 3169– 3179
chains  with one additional apiose unit 1 → 3 linked to the rham-
nose unit of the C-28 carbohydrate chain (Fig. 1). The QS21 saponin
on the other hand is more complex but also, similar to the C. alba
saponins, shows a triterpene nucleus to which is attached one glu-
curonic acid at C-3, substituted with galactose and xylose and a
5-sugar-unit chain (rhamnose–xylose–apiose and fucose and ara-
binose) at C-28 that also includes a hydrophobic moiety composed
of 2 normonoterpenes [29].
In this investigation we pursued the analysis of the adjuvant
potentials of CA3 and CA4 saponins of C. alba aiming to identify if the
addition of one sugar unit has any impact on the immunoprotective
potential of the saponin.
2.  Materials and methods
2.1.  Ethical statements
All  mouse studies followed the guidelines set by the National
Institutes of Health, USA and the Institutional Animal Care and Use
Committee approved the animal protocols (Biophysics Institute-
UFRJ, Brazil, protocol IMPPG-007).
2.2.  Isolation of saponins of C. alba (L.) Hitch
Samples of C. alba were collected in Nova Friburgo, Rio de
Janeiro, Brazil. The botanical identiﬁcation was made by Dr.
Sebastião Neto, and a voucher specimen (RB395399) has been
deposited in the Herbarium of the Rio de Janeiro Botanical Gar-
den. Air-dried and powdered roots of C. alba (400 g) were extracted
with ethanol. The extract was evaporated and the residue obtained
(12 g) was  suspended in water and successively partitioned with
methylene chloride and butanol. The butanol fractions were com-
bined, evaporated and the residue (4 g) was suspended in methanol
and subjected to controlled precipitation with diethyl ether.
The precipitate (2 g) was fractionated by column chromatogra-
phy (octadecylsilane, 60 cm × 20 cm)  using H2O with increasing
proportions of methanol (0–100%) to obtain 10 fractions. TLC
tests carried out with Liebermann–Bouchard and sulfuric orci-
nol reagents together with the observation of an abundant foam
formation, allowed the identiﬁcation of the saponin enriched frac-
tions. Further puriﬁcation was  carried out with reversed-phase
(octadecylsilane) preparative HPLC using methanol: 0.02% aqueous
triﬂuoroacetic acid (60:40; v/v) to obtain 48 mg  of CA3 (Chiococca
saponin II) and 78 mg  of CA4 (Chiococca saponin I) [28]. We  also
collected and identiﬁed two  other saponins of C. alba to be used as
controls: the CA2 (18 mg)  and the CA3X (10 mg)  (Fig. 1). All saponins
(CA4, CA3, CA3X and CA2) share a triterpene nucleus to which a
glucuronic acid is attached at C-3 and a rhamnose and arabinose
containing chain is attached at C-28 (Fig. 1). The CA3X and CA3 have
a third sugar attached 1 → 4 to the rhamnose unit. This third sugar is
xylose in CA3X and apiose in CA3. The CA4 saponin has, in addition
to the 1 → 4 linked apiose present in CA3, a fourth apiose unit, 1 → 3
linked to the rhamnose unit of the C-28 carbohydrate chain (Fig. 1).
The hydrophile–lipophile balance (HLB) value of the saponins was
calculated theoretically by the Davies and Riedel method [30] con-
sidering their chemical structure as previously described by Borges
et al. [28] and represented in Fig. 1. The value was calculated by
integrating the number of each functional group composing the
saponin molecule with the group unit deﬁned by the Davies method
(HLB = 7 +
∑
hydrophilic groups −∑ lipophilic groups) [30].
2.3. Hemolytic assayNormal  human red blood cell suspension (0.1 ml  of 0.5%) was
mixed with 0.1 ml  diluent containing 5, 10, 20, 30, 40, 50, 100, 250
and 500 g/ml concentrations of the Riedel de Haën and the CA4,
D. Nico et al. / Vaccine 30 (2012) 3169– 3179 3171
Saponins of Chiococca alba (L.) Hitch 
O
HO
HO
OH
HOOC
O
O
OH
HO
O
Me
OHO
HO
HO
O
O
O
O
OH
HO
CA3 
HLB = 15.8
glucuronicacid 
apiose rhamnose 
arabinose 
O
HO
HO
OH
HOOC
O
O
OH
HO
HO
Me
O
O
O
O
OH
HO
CA2 
HLB = 12.7
glucuronic acid 
rhamnose
arabinose 
3β-hydroxyolean-12,15-dien-28-oicacid 
O
HO
HO
OH
HOOC
O
O
OH
O
O
Me
OHO
HO
HO
O
O
O
O
OH
HO
O
HO
HO
CA4 
HLB = 19.9
glucuronic acid 
apiose 
apiose 
rhamnose 
arabinose 
O
HO
HO
OH
HOOC
O
O
OH
HO
O
Me
O
O
O
O
OH
HO
O
HO
HO
OH
CA3X
HLB = 15.8
glucuronic acid 
rhamnose 
arabinose 
xylose 
2 sapo
C
b
h
4
a
b
v
c
i
e
r
a
F
b
0
2
o
e
l
m
2
o
o
i
t
c
s
nHO
Fig. 1. Chemical structure of the CA4, CA3, CA3X and CA
A3, CA3X and CA2 saponins in saline solution. Mixtures were incu-
ated for 30 min  at 37 ◦C and centrifuged at 70 × g for 10 min. Free
emoglobin in the supernatants was measured by absorbance at
15 nm [21]. Saline and distilled water were included as minimal
nd maximal hemolytic controls. The hemolytic percent developed
y the saline control was subtracted from all groups. The adju-
ant concentration inducing 50% of the maximum hemolysis was
onsidered as the HD50 (graphical interpolation). Each experiment
ncluded triplicates at each concentration. A series of 3 independent
xperiments was performed for the analysis of each HD50. Human
ed blood cells for the hemolytic assay were obtained from healthy
dult blood bank donors (Hospital Universitário Clementino Fraga
ilho, Universidade Federal do Rio de Janeiro, RJ, Brazil). The red
lood cell suspension was prepared by ﬁnally diluting the pellet to
.5% in saline solution.
.4.  In vivo saponin toxicity
Toxicity (assessed by lethality, local pain, local swelling, and loss
f hair) was tested in the vaccinated mice that received 100 g of
ither Riedel de Haën or each one of the C. alba saponins formu-
ated with the FML  antigen, as three weekly doses. The mice were
onitored for seven days after each vaccine dose.
.5. Immunization and parasite challenge by Leishmania chagasi
Eight-week-old female Balb/c mice, received 3 doses of 150 g
f the FML  antigen [9] and 100 g of either the CA3, CA4 saponins
f C. alba or of the Sigma-Riedel de Haën 16109 saponin [reviewed
n 3] on the back, through the sc route, at weekly intervals. At
he beginning of week 4, mice were challenged with 3 × 107 L.
hagasi amastigotes obtained from infected hamster spleens. The
train used for challenge in this study (IOC-L 3324) was origi-
ally isolated from the spleen of an infected dog of Andradina,nins isolated from the roots of Chiococca alba (L.) Hitch.
São  Paulo, Brazil and taxonomically characterized as Leishmania L.
chagasi by the CLIOC-WDCM 731 (Instituto Oswaldo Cruz Leishma-
nia collection, Rio de Janeiro, Brazil). Fifteen days after infection,
mice were euthanized with ether and the parasite load was  evalu-
ated in Giemsa-stained liver smears and expressed in LDU values
(Leishman Donovan units of Stauber = number of amastigotes per
600 liver cell nuclei/mg of liver weight) as described [reviewed in
3]. The increase in total body weight and liver/corporal relative
weight were also recorded as clinical signs of VL. Control exper-
iments in Balb/c female mice also included groups treated with
saponins CA2 and CA3X.
2.6.  Detection of antibodies
Seven  days after immunization and 15 days after infection with
L. chagasi, antibodies of sera were measured by an ELISA assay
against FML  antigen as previously described [31], using 2 g anti-
gen per well and Protein-A peroxidase (KPL, Kirkegaard & Perry
Laboratories, Inc.) or goat anti-mouse IgG1, IgG2a, IgG2b, IgG3,
IgM and IgA horseradish peroxidase conjugated antibodies (South-
ern, Biotechnology Associates, Birmingham, AL, USA) in a 1:1000
dilution in blocking buffer. The reaction was developed with O-
phenyldiamine (Sigma), interrupted with 1 N sulfuric acid, and
monitored at 492 nm.  Each individual serum was  analyzed in trip-
licate in double-blind tests. Positive and negative control sera were
included in each test. Results were expressed as the mean of the
absorbance values (492 nm)  of the 1/100 diluted sera of each ani-
mal.
2.7. Assessment of the speciﬁc T cell immunitySeven days after immunization and 15 days after infection with
L. chagasi, the intradermal response against L. donovani lysate (IDR)
was measured in the footpads as described earlier [32]. Brieﬂy, mice
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IgM, a signiﬁcant enhancement was also noted after infection in
the saline controls. Following the R saponin positive control, the
CA4 saponin raised more IgG and IgG2a antibodies to the FML  anti-
gen than the CA3 saponin (Fig. 2). Indeed, the average absorbance of
Fig. 2. Antibody analysis. Bars represent the mean ± SE of the absorbance values
of  anti-FML antibodies from 1/100 diluted serum of two independent experiments
using  n = 6–8 mice per treatment in each experiment, after immunization and after
7172 D.  Nico et al. / Vacc
ere injected intradermally, in the right hind footpad, with 107
reeze–thawed stationary phase Leishmania donovani promastig-
tes (LD-1S Sudan strain) (200 g of protein) in 0.1 ml  sterile saline
olution. The footpad thicknesses were measured with a Mitutoyo
pparatus, both before and 0, 24 and 48 h after injection. Inject-
ng each animal with 0.1 ml  saline in the left hind footpad served
s control. At each measurement, the values of the saline control
ere subtracted from the reaction due to the Leishmania antigen.
revious experiments carried out in Balb/c mice and CB hamsters
emonstrated that 24 h after inoculation saline treated footpads
eturned to base levels [32].
We also compared the IDR induced in immunized and in chal-
enged mice by the injection of either the promastigote lysate
200 g of protein), or the FML  antigen (100 g), or the NH36
ecombinant protein (100 g), in 0.1 ml  of saline solution.
Further analyses of cellular immune responses was  carried out
sing 106 splenocytes after 5 days of in vitro culturing at 37 ◦C
nd 5% CO2 in RPMI medium and/or 5 g of recombinant NH36,
he main antigenic component of the FML  antigen [31]. Secre-
ion of IFN- and TNF- was evaluated in the supernatants of
n vitro cultured splenocytes by an ELISA assay, using the Biotin
at anti-mouse IFN- (clone XMG1.2), the puriﬁed Rat anti-mouse
FN- (clone R4-6A2) and the Mouse TNF ELISA Set II kit (BD
ioscience Pharmingen) according to the manufacturer’s instruc-
ions. Flow cytometry analysis (FACS analysis) in a FACScalibur
pparatus was performed after splenocyte immunostaining with
nti-CD4 (clone GK1.5) or anti-CD8-FITC (clone 53-6.7) mono-
lonal antibodies (R&D systems, Inc.). The intracellular production
f IFN-, TNF- and IL-10 cytokines by CD4+ and CD8+ T cells
as determined using 10 mg/ml  brefeldin (Sigma) for 4 h at 37 ◦C
nd 5% CO2 followed by washing with FACS buffer (2% fetal calf
erum, 0.1% sodium azide in PBS). Cells were labeled for 20 min
t 4 ◦C in the dark with rat anti-mouse CD4FITC and CD8FITC
R&D systems) in FACS buffer (1/100). After that they were ﬁxed
ith 4% paraformaldehyde, washed and treated with FACS buffer
ith 0.5% saponin (Sigma) for 20 min  at room temperature and
hen further stained with IFN--APC, TNFPE and IL-10PE mono-
lonal antibodies (BD-Pharmingen), 1/100 diluted in FACS buffer
ith 0.5% saponin for 20 min, and ﬁnally washed and resus-
ended in FACS buffer. A total of 30,000 cells were analyzed
y ﬂow cytometry in a Becton Dickinson FACScalibur apparatus,
nd further analyzed using WinMDI (Windows Multiple Docu-
ent Interface Flow Cytometry Application) Version 2.8 software
31].
In vivo depletion of CD4+ or CD8+ T cells was performed by treat-
ng CA4 saponin and FML  vaccinated mice with GK1.5 or 53.6.7 rat
gG MAb  on days 2, 4 and 6 before challenge and on day 7 after chal-
enge. Control mice received the CA4-FML vaccine and 0.05 mL  of
at serum through the intraperitoneal route, equivalent to 0.25 mg
f IgG, or nude mice ascitic ﬂuids containing 0.25 mg  of anti-CD4+
nd/or anti-CD8+ antibodies. As determined by FACS analyses, the
fﬁcacy of depletion of CD4+ or CD8+ spleen cells before chal-
enge was of 99.94% or 96% in anti-CD4+ or anti-CD8+ treated mice,
espectively. The efﬁcacy of depletion treatment was  monitored by
he increase in liver parasite load and liver relative weight, 15 days
fter infection.
Randomly selected female TNF KO mice (n = 15) and their wild-
ype (WT) littermates (n = 15), generated on a C57BL/6 background,
ere used in these experiments. Groups of ﬁve mice were vacci-
ated with CA3 or CA4 saponin in combination with FML-antigen
r with saline and were injected via the tail vein with 3 × 107 ham-
ter spleen-derived L. chagasi amastigotes (IOC-L 3324). The IDR
as determined after immunization and 15 days after infection,
isceral infection was monitored microscopically using Giemsa-
tained liver imprints, and liver parasite burdens were measured
n livers by counting in a blinded fashion the amastigotes per 600 (2012) 3169– 3179
cell  nuclei and multiplying this number by the liver weight in mil-
ligrams (LDU units).
2.8.  Statistical analysis
Differences  between means were compared by the
Kruskall–Wallis (KW) and Mann–Whitney (MW)  non-parametrical
tests (Analyze-it). For the analysis of dependent data of the same
individuals before and after infection the Wilcoxon Signed-Rank
two-tailed test was used, which is the non-parametric alternative
of the t-test for correlated samples of the VassarStats program
(http://faculty.vassar.edu/lowry/wilcoxon.html) [33]. Correlation
coefﬁcient analysis was  determined using a Pearson bivariate, two
tailed test of signiﬁcance (SPSS for windows).
3. Results
3.1. Assessment of the anti-FML humoral response
After complete immunization signiﬁcant differences in anti-
FML antibodies were found among treatments for IgM, IgG, IgG1,
IgG2a, IgG2b and IgG3 (p < 0.01 for all antibody types) but not for
IgA antibodies (p = 0.7331). The CA3, CA4 and R saponins raised the
IgM, IgG1 and IgG3 antibody levels above the respective saline con-
trols (Fig. 2). The CA3 vaccine induced 54% and 76% of the IgM and
the IgG1 absorbency values induced by the saponin R positive con-
trol, respectively. The CA4 vaccine, on the other hand, induced 62%
and 82% of the total IgM and IgG1 response generated by saponin
R, respectively. We  conclude that after immunization both C. alba
saponins induced a predominant IgM, IgG3 and IgG1 anti-FML anti-
body response.
After challenge, on the other hand, signiﬁcant differences
between groups were found in anti-FML IgG (p < 0.0001), IgG1
(p < 0.0001), IgG2a (p < 0.0001), IgG2b (p = 0.0094) and IgG3
(p = 0.0003) but not for IgA (p = 0.5164) or IgM (p = 0.0783) antibod-
ies. As disclosed before challenge, the IgG1 and the IgM antibodies
were strongly enhanced by all the saponins (Fig. 2). In the case ofchallenge with 3 ×10 amastigotes. Signiﬁcant differences to the saline controls
(*);  to the saponin R vaccine positive control (©); and to the FML-CA3 vaccine
treatment  () as disclosed by the Kruskall–Wallis (KW) and Mann–Whitney (MW)
non-parametrical  tests.
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A4 increased from 0.564 before to 1.189 after infection (p = 0.0079)
hile the average for CA3 vaccinated mice did not signiﬁcantly
hanged (from 0.718 to 0.689; p = 0.114). Furthermore, the CA4sap
accine IgG2a response after infection was not statistically different
rom the saponin R vaccine. All saponins raised equivalent levels
f IgG1 above the saline control and only the R saponin signiﬁ-
antly enhanced the IgGb and IgG3 antibodies above saline controls
Fig. 2). The IgA antibodies, on the other hand, were enhanced in all
roups after challenge (Fig. 2).
The predominance of the CA4 saponin, although only modest
fter immunization, was more evident after infection. Indeed, com-
ared to the respective antibody titers before infection, signiﬁcant
ncreases were detected in the CA4 saponin vaccinated mice after
hallenge for IgA (p = 0.0032), IgM (p = 0.0124), IgG (p = 0.0414),
gG2a (p = 0.0061) and IgG2b (p = 0.0349) antibodies while the CA3
aponin vaccine only showed an increase of the IgA (p = 0.0016)
nd IgM antibodies (p = 0.0045). These results conﬁrm the higher
otency of the 4 sugar chain CA4 saponin (Fig. 1) in the induction
f anti-FML speciﬁc antibodies that was further enhanced after the
nfective challenge.
.2.  Assessment of the intradermal response to leishmanial
ntigen (IDR)
The  cellular immune response was initially evaluated by the
ntradermal reaction against Leishmania lysate (IDR) (Fig. 3). IDR
as measured in the right hind footpads and subtracted from the
alues of the left hind footpad injected only with saline. At 24 h
fter immunization, the IDR response was signiﬁcantly higher for
he R saponin compared to all the other groups and also higher for
he CA3 (mean = 0.06 mm)  and CA4 (mean = 0.08 mm)  than for the
aline control (mean = 0.02 mm)  (Fig. 3A). At 48 h only the R and
A4 sustained this response indicating the superiority of CA4 over
he CA3 saponin of C. alba. After challenge, only the R saponin vac-
ine sustained the enhanced IDR (Fig. 3B). There was  no signiﬁcant
ariation, before and after infection, in the magnitude of the IDR
esponse induced by the CA3 (p = 0.8103 at 24 h and p = 0.6818 at
8 h) or by the CA4 vaccines (p = 0.3898 at 24 h and p = 0.2801 at
8 h) (Fig. 3A and B).
In an additional experiment we compared the abilities of
he Leishmania promastigote lysate, the FML  antigen that was
sed for vaccination and the NH36 recombinant protein, which
s the main antigenic component of FML  for the induction of
DR (Fig. 4). Although the same trend described in Fig. 3A was ** from all treatments as disclosed by the Kruskall–Wallis (KW) and Mann–Whitney
observed,  the predominance of the CA4 IDR against the Leish-
mania lysate was  in this experiment even more pronounced
(mean = 0.416 mm and 0.430 at 24 h, before and after challenge,
respectively) (Fig. 4A and C). The CA3 vaccine, on the other hand,
showed means = 0.202 and 0.217 at 24 h, before and after challenge,
respectively (Fig. 4A and C). In this experiment, the predominance
of the CA4 saponin vaccine was sustained even after challenge.
IDR reactions after injection with either FML  or NH36 antigens
were higher in mice vaccinated with CA4 than with CA3 saponin.
While all reactions to promastigote lysate were sustained after
challenge, the IDR to FML  or NH36 antigens showed to be reduced
(Fig. 4C and D).
3.3.  Assessment of the speciﬁc T cell immunity by ﬂow cytometry
analysis and intracellular production of cytokines
Following the analysis of the cellular immune response, the
increase of the percents of spleen Leishmania-speciﬁc T cells after
challenge was  evaluated by ﬂuorescent cytometry analysis (Fig. 5).
We observed that only the CA4 vaccine increased both the CD4+
and the CD8+ Leishmania-speciﬁc T cell proportions over the saline
controls while the CA3 vaccine increased only the CD8+ speciﬁc T
cell proportions (Fig. 5). There was  no difference between the CA3
and CA4 vaccines to the gold standard R. Finally, the splenocytes
were also labeled through the ICS method and the results are shown
as double positive cells (Fig. 6). We observed that the CA4 vaccine
induced enhancements of the TNF--producing CD4+ T cells and of
the IFN--producing CD8+-T cells while the CA3 vaccine induced
the increase of the IFN--producing CD4+-T cell proportions. No
signiﬁcant variations among treatments were observed in the pro-
portions regarding the TNF- or the IL-10 production by the CD8+
T cells.
3.4. Protective efﬁcacy to infection by L. chagasi
The analysis of the parasite load in livers showed that all
vaccines induced protection when compared to saline con-
trols (p < 0.0001) (Fig. 7). Besides the QS21 containing saponin
positive control which induced a 89% signiﬁcant reduction,
in agreement with the above described results of the anal-
ysis of the immune response, the C. alba CA4 induced
the highest protection (78%, p < 0.0001) that was followed
by the CA3 saponin with 57% (p < 0.0001) of parasite load
reduction. The difference between CA4 and CA3 was signiﬁcant
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p < 0.0125) hence conﬁrming the superiority of the CA4 saponin in
rotection against visceral leishmaniasis (Fig. 7). The gain in body
eight along the experiment induced by R saponin was superior to
hat of the saline controls (p = 0.0407) but not signiﬁcantly differ-
nt from the increases in the CA3 and CA4 saponin vaccinated mice
not shown).
The  increases in IDR after vaccination and infection were strong
orrelates of protection and were signiﬁcantly correlated to the
ecrease of parasite load (p = −0.007) and to the gain in corpo-
al weight (p = 0.0001). The increases in CD4–TNF- (p < −0.001),
D8–IFN- (p < −0.002) and CD8–TNF- (p < −0.015) expressing T
ell proportion were also correlated to the decrease of parasite
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3.5. In vivo depletion assay of CD4+ and CD8+ T cells
The relative contribution of the NH36-speciﬁc-CD4+ and CD8+ T
cell producing cells was evaluated in an in vivo depletion assay with
monoclonal antibodies (Fig. 8). In correlation to what was detected
for the speciﬁc increase of the CD4+ T cells (Fig. 5), the TNF-–CD4+
producing T cells (Fig. 6), only the treatment with anti-CD4+ mon-
oclonal antibody induced a 66% increase in the total LDU counts of
mice vaccinated with CA4 saponin, indicating a main contribution
of CD4+ T cells (Fig. 8; p > 0.05) to the vaccine induced protection.
On the other hand, the protective effect of the CA3-vaccine is medi-
ated by both CD4+ and the CD8+ T cell contributions since the
anti-CD4+ antibody treatment induced a 43% and the anti-CD8+
antibody induced a 16% increase of the total LDU counts of CA3
vaccinated mice, respectively (Fig. 8). This is in agreement with the
increase of the percent of CD8+ NH36-speciﬁc T cells by the CA3
vaccine (Fig. 5) and of the IFN--CD4+ producing T cells (Fig. 6).
The increases in IDR, CD4–TNF-, CD8–IFN- and CD8–TNF- by
the CA4 vaccine were strong correlates of protection and were sig-
niﬁcantly correlated to the decrease of parasite load (p = −0.007).
3.6. TNF-  ˛ contribution to protection
To conﬁrm the relevance of TNF- in the protection induced by
C. alba we  vaccinated C57BL6 wild-type and TNF--receptor knock-
out mice and challenged them with L. chagasi amastigotes. The
IDR response against Leishmania lysate was signiﬁcantly increased
(81%) only by the CA4 saponin vaccine in wild type mice above
their respective saline control (Fig. 9). No increases in IDR were
observed however in vaccinated TNF--knock-out mice (Fig. 9).
Different from what was  detected in Balb/c mice treated with saline
(mean = 415 LDU units) (Fig. 7) the C57Bl6 strain was more sensitive
(mean = 1200 LDU units). Conﬁrming the role of IDR as a correlate of
D. Nico et al. / Vaccine 30 (2012) 3169– 3179 3175
IFN- -CD4+
IFN-  -CD8+
0.0
0.5
1.0
1.5
2.0
* 
TNF- -CD4+
0.0
0.5
1.0
1.5
2.0 * 
IL-10-CD4+
0.0
0.5
1.0
1.5
2.0
c
y
to
k
in
e
 p
ro
d
u
c
in
g
 c
e
lls
 (
%
) 
  
  
  
  
  
  
  
  
  
 c
y
to
k
in
e
 p
ro
d
u
c
in
g
 c
e
lls
 (
%
) 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
sal 
CA3 
CA4 
R 
* 
TNF- -CD8+
0.0
0.5
1.0
1.5
2.0
2.5
3.0
IL-10-CD8+
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Fig. 6. Development of NH36-speciﬁc cellular immune response as disclosed by intracellular staining analysis of splenocytes in vitro culture with NH36 after L. chagasi
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3.7. Correlation between the increase of the sugar chain and
cytokine  secretion
To  conﬁrm that the presence of an extra-apiose in CA4 is
responsible for its increased adjuvant potential, we compared the
protective efﬁcacy of the CA3 and CA4-vaccines to the one of vac-
cines formulated with the CA3X and CA2 saponins of C. alba (Fig. 1).
All these saponins are naturally produced through a glycosylation
series by the C. alba plant. The shorter chain is present in CA2 which
has only an arabinose and a rhamnose unit attached to C-28 (Fig. 1)
and is followed by the CA3X and CA3 saponins, both with three sug-
ars attached to the C-28 chain. The third sugar is xylose for CA3X
and apiose for CA3. Finally, the CA4 shows the same arabinose,
rhamnose and apiose chain present in CA3 and an additional extra
apiose (Fig. 1). The cellular immune response was  also analyzed
by monitoring the secretion of cytokine by splenocytes of vacci-
nated and challenged mice after in vitro incubation with the NH36
antigen. The results are summarized in Fig. 10. The ELISA-analysis
of the cytokines secreted by splenocytes after in vitro incubation
with NH36 antigen was performed after challenge (Fig. 10). The
secretion of TNF- was  increased by the CA3X, CA4 and the con-
trol R vaccines while the secretion of IFN- was enhanced above
the saline control only by the control R vaccine. The IL-10 secre-
tion was  enhanced only by the CA4 vaccine. It is worth noting that
the increase in the number of sugar units of the C-28 attached to
the carbohydrate chain of saponins is positively correlated to the
increase in secretion of TNF- (p < 0.001) and of IFN- (p = 0.026)
and to the decrease in secretion of IL-10 (p = −0.008). Secretion of
TNF- was more intense than that of IFN-. Our results disclose the
protective adjuvant potential of CA3 and CA4 saponins and suggest
that the addition of one sugar unit on the C-28 attached chain of
CA4 determines a signiﬁcant increase in its adjuvant potential.
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.8. Correlation between the increase of the sugar chain, IDR and
he  decrease of parasite load
Furthermore, the impact of the increase of the C-28 attached
ugar chain of C. alba was compared in the Balb/c mice model,
sing the CA2 and the CA3X saponins (Fig. 1) as controls. The IDR
esponse was enhanced only by the CA4 and the R saponin above
he saline controls (Fig. 11). In correlation to that, only the CA4 and
he R saponin reduced the parasite load when compared to saline
ontrol (Fig. 11), conﬁrming the superiority of CA4. The reduction
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s described in Fig. 7, not different from the protection induced
y CA3. Maximal parasite load reduction was achieved by the R
aponin control group (Fig. 11). There was a positive correlation
etween the increase in IDR measures and in the number of sugar
nits attached to the triterpene-C-28 (p < 0.0001). Supporting our
ypothesis of the superiority of the CA4 saponin, on the other hand,
he LDU values decreased with the increase of the sugar chain
p = −0.014).
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3.9. Assessment of the hydrophile–lipophile balance (HLB) value,
hemolytic  index and in vivo toxicity of saponins
The hydrophile/lipophile balance calculation performed accord-
ing to the Davies and Riedel method disclosed an HLB = 12.7 for CA2,
HLB = 15.8 for both CA3 and CA3X and an HLB = 19.9 for CA4 saponin
conﬁrming its higher hydrophilicity.
The  analysis of the hemolytic capacity of C. alba saponins
(Table 1) disclosed that saponins CA2, CA3 and CA4 share a high
HD50 (175 g/ml) which means that they are poorly hemolytic and
that the hemolytic capacity, differently from what happens with
the HLB, does not increase in positive correlation with the number
of sugar units linked to the sapogenin. The saponin CA3X, with 3
sugar units attached to C-3 of triterpene, but not apiose, induced,
on the other hand, a strong hemolysis (HD50 = 87 g/ml) (Table 1).
The control saponin R, was as expected the most hemolytic
(HD50 = 35 g/ml). Furthermore, the safety analysis detected nei-
ther lethality nor local pain or swelling (Table 1) for any of the C.
alba vaccines. Only loss of hair at the local of injection was detected
in the 5 mice treated with the QS21 containing saponin R.
4.  Discussion
The increase in hemolytic activities of C. alba saponins was
not correlated to the increase in the size of the C-28 attached
carbohydrate chain. In contrast, the CA3 and CA3X saponins that
both have three sugar units in that chain strongly differed in their
hemolytic capabilities. Saponin CA3X which has a xylose termi-
nal unit induced strong hemolysis while saponin CA3 that shows
an apiose unit instead was much less hemolytic. In correlation
with our ﬁndings, the QS21 adjuvant is composed of two  isomers
that include either apiose (QS21-Api) or xylose (QS21-Xyl) as the
terminal sugar residue within the linear tetrasaccharide segment,
in a ratio of 65:35, respectively [34]. The saponin QS21-Xyl was
marginally more toxic than QS21-Api or the QS21 mixture. Over-
all mice weight loss was  greatest in the SQS21-Xyl groups and
although one mouse of both groups died over the course of immu-
nizations, the mice in the QS21-Xyl group showed the worst clinical
status. On the other hand, the QS21-Xyl treated mice induced a
higher IgM and IgG response [34].
In our investigation we  demonstrated that the adjuvant poten-
tial of C. alba saponins is correlated to the increase of their C-28
attached sugar chain. We  also demonstrated that the addition of
an extra apiose unit in CA4 saponin is determinant of its enhanced
adjuvant potential. Both the CA3 and CA3X saponins have three
sugar chains and three exposed hydroxyl groups on the terminal
sugar unit, therefore sharing the same HLB. However the spa-
tial conﬁguration and exposition of the HO groups on the apiose
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Fig. 10. Development of NH36-speciﬁc cellular immune response. ELISA of cytokines in supernatants of mice splenocytes. IFN-, TNF- and IL-10 were assayed in the
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the  saline control as disclosed by the Kruskall–Wallis (KW) and Mann–Whitney (MW)  no
Fig. 11. Parasite load reduction increases with sugar chain of saponins. Balb/c mice
were vaccinated with the CA2, CA3, CA3X, CA4 or R saponin and FML  or treated
with  saline only and further challenged with L. chagasi amastigotes. The intrader-
mal  reaction to promastigote lysate, at 24 h after antigen injection, is expressed
in  millimeters. The individual L. chagasi liver parasite load values are expressed
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indicates signiﬁcant differences as disclosed by the Kruskall–Wallis (KW) and
Mann–Whitney  (MW)  non-parametrical tests.
Table 1
Toxicity in vivo and hemolytic effect of saponins.
Saponin Local pain Swelling Loss of hair Lethality HD50
R (QS21) 0/5 0/5 5/5 0/5 35 g/ml
CA4 0/5 0/5 0/5 0/5 175 g/ml
CA3 0/5 0/5 0/5 0/5 175 g/ml
CA3X 0/5 0/5 0/5 0/5 87 g/ml
CA2 0/5 0/5 0/5 0/5 175 g/ml
Note: Results are expressed as number of mice per group that showed any reac-
tivity  within 7 days after each one of the three subcutaneous injections of each
vaccine containing 100 g of saponin in the back of each animal. HD50 is the adjuvant
concentration  inducing 50% of the maximum hemolysis.e with the NH36 antigen. Data correspond to individual results of one experiment
al full lines represent the mean values. *p < 0.05 indicates signiﬁcant differences to
n-parametrical tests.
terminal sugar unit is optimized when compared to the conﬁgu-
ration of the same groups in xylose. This would explain also the
reason for the increased adjuvant potential of CA4 which has an
additional apiose unit.
The  CA4 saponin of C. alba in formulation with FML  induced
a higher response after challenge, signiﬁcant increases in IgG and
IgG2a anti-FML antibodies which were absent in the CA3-saponin.
These results conﬁrm the relevance of the addition of a fourth
unit of apiose 1 → 3 linked to the rhamnose residue of the C-28
attached sugar chain in the induction of the anti-FML humoral
response. As expected for a positive adjuvant control, the global
humoral response induced by the saponin QS21 containing saponin
R vaccine was the highest. The intensity of the humoral response
generated by saponins has been shown to be related to the pres-
ence of carbohydrate moieties attached to the triterpene nucleus
[14,17,25] and this response increases in direct proportion to their
length [22]. This explains why, even in a saponin with only 4 sugar
units chain (CA4), the difference of just one sugar residue [28] may
account for a signiﬁcant increase in IgG and IgG2a speciﬁc antibod-
ies which are the subclasses of antibodies previously shown to be
correlated to protection.
In  our investigation, all saponins increased the IgG1 antibod-
ies. This humoral response is induced by whole saponins [23] but
seems to be correlated to the carbohydrate deprived sapogenin
nuclei [14,17]. A global increase of IgM and IgG3 antibodies by all
adjuvants was described which is expected to occur in response to
carbohydrate enriched antigens [35] and saponins [14,17].
The  sugar side chain in saponins may  be essential to their
adjuvanticity [reviewed in 22]. Soyasaponins that comprise sugar
chain(s) have shown adjuvanticity stimulating anti-OVA total-IgG
and IgG1 antibody responses while their corresponding agly-
cones soyasapogenols A and B, did not. The CP05 saponin of C.
pulcherrima induced a strong antibody response that was main-
tained after removal of its monoterpene hydrophobic moiety but
not after removal of the C-28 and or the C-3 attached glyco-
sidic chains [14]. With the removal of these glycosidic chains
the CP05 aglycone only sustained the IgG1 and the IgM response
[14]. Oda et al. [25] described that the adjuvanticity of saponins
increases with their hydrophile–lipophile balance (HLB). Indeed,
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he capability of saponins to induce antibody responses increases
ith their hydrophilicity. Among bidesmosidic (two sugar chains)
oyasaponins, soyasaponin A1 with three sugars attached to C-
 induced stronger total-IgG and IgG1 antibody responses than
oyasaponin A2 with only two sugar attached to C-3 [25]. An
dentical conclusion was obtained by Bernardo et al. [19] working
ith the PSAGLE saponin of Albizia saman. For monodesmosidic
one sugar chain) soyasaponins, the ranking in terms of anti-
ody response was soyasaponin I (-glcA-gal-rha) > soyasaponin II
-glcA-ara-rha) > soyasaponin III (-glcA-gal) [25]. This means that
 trisaccharide (soyasaponin I and II) chain is more potent than a
isaccharide one (soyasaponin I), and that a residue of galactose
n the trisaccharide chain of soyasaponin I that exposes one OH
roup turns the saponin more potent than a residue of arabinose
hich lacks this OH group (soyasaponin II) [25]. Therefore, among
aponins of the same sugar chain length, the more hydrophilic the
ugar components are, the more potent the humoral response is.
he C-28 attached chain of the C. alba CA3 saponin is composed
f arabinose–rhamnose–apiose. The addition of one additional
piose sugar unit in the CA4 saponin is then expected to add
ydrophilicity to the saponin [25] increasing its adjuvant poten-
ial. Our results with saponins of C. alba therefore, strongly support
he previous conclusions of Oda et al. [25] stating that the adju-
ant activity tended to increase with the sugar side chain length
nd the HLB value. Indeed, this investigation reported HLB values
f 15.8 and 19.9 for CA3 and CA4 saponins, respectively. The HLB
f QS21 saponin, which is a highly potent standard adjuvant, is
6.3 [25]. The saponins of C. alba display lower HLB values than
S21 and bidesmosidic soyasaponins but higher HLB values than
onodesmosidic soyasaponins [25].
The extra-apiose of CA4 saponin determines the increase of the
-28 sugar chain length and, in this way, of the saponin hydrophilic-
ty. In order to conﬁrm that HLB is a crucial factor inﬂuencing
he adjuvanticity of the CA4 saponin we used as controls, the CA2
nd CA3X saponins of C. alba, that have shorter sugar chains since
hey are synthesized in earlier steps of the biosynthetic pathway.
ndeed, the triterpene nucleus is synthesized ﬁrst and the sugar
nits added in sequence to its C-28 by speciﬁc glycosyltransferases
36]. Our results conﬁrmed the correlation between increased HLB
nd increased adjuvant capabilities.
As expected for protection generated against visceral leishmani-
sis [31,37–44] protection induced by CA4 saponin determined the
ecrease of liver LDU and the increases of IDR and of TNF-–CD4+
roducing cells and TNF- secretion. The protection induced by
he CA4-vaccine was mediated a CD4+ T cell and TNF--driven
esponse. This could indicate the existence of an early effector cell-
esponse generated by the vaccine [45]. TNF- is considered to
e the most ubiquitous cytokine and it is produced by most acti-
ated CD4+ T cells [reviewed in 45] generated under conditions
hat favor TH1-cell differentiation. It has proved to be important
n protection against visceral leishmaniasis [37–44,46,47]. A sus-
ained or an overall increased global or Leishmania-speciﬁc CD4+
 cell expansion is expected in protection against visceral leish-
aniasis [31,48]. In our investigation, the CA4 saponin, with the
ongest sugar chain was the only one capable of enhancing the CD4+
eishmania-speciﬁc T cell population.
Also, supporting our results, a study of the relationship between
emolytic and adjuvant activity and structure of protopanaxadiol
nd protopanaxatriol-type saponins from the roots of P. notoginseng
howed that the number, length and position of sugar side chains,
nd the type and the linkage of the glycosyl group in the structure
f these saponins did not only affect the adjuvant potentials, but
lso had signiﬁcant effects on the nature of the immune responses
20,21].
We conclude that the addition of one sugar unit in the C-28
ttached glycosidic moiety provides a signiﬁcant increase of
[
[ (2012) 3169– 3179
adjuvanticity  and protective capability of the C alba saponins.
Our results encourage the new synthesis or remodeling of natural
saponins by additional glycosylation, aiming the rationale devel-
opment of effective adjuvants. This has proven to be feasible since
the most frequent isomer of QS21 saponin which has also apiose as
the terminal sugar unit of its C-28 chain, was obtained by chemical
synthesis while maintaining the adjuvant capability of the natural
product [34].
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